2025-523959-65-00招募中1 期
ADCX-020 for the treatment of patients with locally advanced or metastatic cancers
Adcytherix3 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2026年2月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 55
- 试验地点
- 3
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
clinicaltrials@adcytherix
Scientific
Adcytherix
研究点 (3)
Loading locations...
相似试验
招募中
1 期
A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors previously treated with other therapies.2024-512403-39-01Abalos Therapeutics GmbH27
进行中（未招募）
1 期
QX027N 注射液健康受试者和中重度特应性皮炎受试者 I 期研究CTR2025462965
招募中
1 期
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96
招募中
2 期
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Chronic Inducible Urticaria2024-516988-87-00Celldex Therapeutics Inc.114
招募中
1 期
A phase 1, controlled, open-label, single dose, dose-escalation, clinical proof-of-concept study of MRI enhanced with ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in patients with brain amyloid deposits as demonstrated by amyloid PETAlzheimer's disease2024-520078-36-00Alzeca Biosciences Inc.18